导航
logo
News_Details
There is currently no information to display
Please add data record on website background.
Homepage
>
News
2024-03-21

Jiudian Scholarship Donation Ceremony was held in Xiangtan University

On the occasion of the 50th anniversary of Xiangtan University's re-establishment, Jiudian Pharmaceutical donated 250,000 yuan to Xiangtan University and injected it into the "Xiangtan University Jiudian Pharmaceutical Scholarship Fund" to support poverty students in the School of Chemistry.
Jiudian Scholarship Donation Ceremony was held in Xiangtan University
2024-03-18

Hunan Jiudian Pharmaceutical have Market Authorization of Potassium Sulphate API from NMPA

In the middle of March, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Potassium Sulphate API from NMPA.
Hunan Jiudian Pharmaceutical have Market Authorization of Potassium Sulphate API from NMPA
2024-03-06

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

On March 1, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, focus on production of APIs and excipients, have Ecovadis score for the first time, it is Bronze.
Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024
2024-02-29

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen PepLib Biotech in Changsha China on Feb 28, 2024.
Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.
2024-02-03

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

In Feb, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of dapoxetine hydrochloride and celecoxib API from NMPA.
Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA
2024-02-01

Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA

At the beginning of 2024, PudaoPharma, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had drug license of Ebastine oral solution from NMPA. PudaoPharma is the first enterprise to obtain this dosage form license of Ebastine in China.
Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA
Previous page
1
2
Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China     TEL. 0086-731-88220222     
Copyright © 2019 Hunan Jiudian Pharmaceutical Co., Ltd. 湘ICP备19009736号-2